Company news

Clarity Pharmaceuticals Ltd. (ASX:CU6) news

Clarity Pharmaceuticals Ltd. news releases on 6ix. Latest, Aug 5, 2026: Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose…

Clarity Pharmaceuticals Ltd. (ASX:CU6) news

Press releases & updates

Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses

SECuRE update

Data on SAR-bisPSMA to be presented at EANM

Clarity receives $9.8 million R&D tax incentive refund

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

Clarity signs a Commercial Manufacturing Agreement

Co-PSMA data published in the European Urology journal

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

Clarity signs a large-scale Manufacturing Supply Agreement

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

Co-PSMA data presented

Registrational Phase III AMPLIFY trial: Target number of participants achieved

AMPLIFY trial - Target number of participants achieved

Half Yearly Report and Accounts

SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET

SECuRE trial update

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

Co-PSMA abstract released

Quarterly Activities/Appendix 4C Cash Flow Report

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

SECuRE trial to continue with no modifications to protocol

Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026

Co-PSMA abstract accepted for oral presentation at EAU

Positive guidance from the US FDA on Cu-64 SARTATE Phase III

AGM MD Presentation

Clarity signs copper-67 Supply Agreement with Nusano

Co-PSMA trial achieves primary endpoint

S&P DJI Announces September 2025 Quarterly Rebalance

Preliminary Final Report

Clarity successfully completes $203 million institutional pl

Co-PSMA trial: Recruitment successfully completed

Co-PSMA trial recruitment successfully completed

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Clarity enters a Commercial Manufacturing Agreement

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

SABRE topline results

DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.

DISCO topline results

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

First patient imaged in Phase III AMPLIFY trial

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences

AMPLIFY trial commences

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

Clarity signs commercial-scale copper-64 Supply Agreement

$11.1 million RDTI and refocus on high-priority programs

SECuRE trial update: First patient treated in the Phase II Cohort Expansion

First patient treated in the Phase II of the SECuRE trial

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.

Clarity signs Cu-64 Supply Agreement with UQ

Appendix 4D